| Literature DB >> 30858970 |
Shravani Mitra1, Suchandra Mukherjee2, Sharmi Naha1, Pinaki Chattopadhyay2, Shanta Dutta1, Sulagna Basu1.
Abstract
Background: The bla NDM-1 (New Delhi Metallo-β-lactamase-1) gene has disseminated around the globe. NDM-1 producers are found to co-harbour resistance genes against many antimicrobials, including fluoroquinolones. The spread of large plasmids, carrying both bla NDM and plasmid-mediated fluoroquinolone resistance (PMQR) markers, is one of the main reasons for the failure of these essential antimicrobials.Entities:
Keywords: Ciprofloxacin; Enterobacteriaceae; India; NDM; Neonates; PMQRs
Mesh:
Substances:
Year: 2019 PMID: 30858970 PMCID: PMC6391786 DOI: 10.1186/s13756-019-0477-7
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Antibiotic susceptibility pattern of the studied isolates
| Antibiotics | Non-susceptible isolates no. (%) | Non-susceptible | Non-susceptible | |
|---|---|---|---|---|
| Piperacillin | 72 (99%) | 15 (94%) | 55 (100%) | 0.5080 |
| Cefotaxime | 68 (93%) | 13 (81%) | 53 (96%) | 0.1274 |
| Cefoxitin | 55 (75%) | 9 (56%) | 44 (80%) | 0.1160 |
| Aztreonam | 65 (89%) | 13 (81%) | 50 (91%) | 0.5311 |
| Meropenem | 36 (49%) | 6 (38%) | 29 (53%) | 0.4306 |
| Ciprofloxacin | 66 (90%) | 12 (75%) | 52 (95%) | 0.0670 |
| Ofloxacin | 58 (79%) | 12 (75%) | 46 (84%) | 0.6753 |
| Amikacin | 55 (75%) | 9 (56%) | 45 (82%) | 0.0756 |
| Gentamicin | 65 (89%) | 11 (69%) | 52 (95%) |
|
| Sulfomethoxazole / trimethoprim | 62 (85%) | 11 (69%) | 49 (89%) | 0.1126 |
| Tigecycline | 16 (22%) | 1 (6%) | 15 (27%) | 0.1523 |
Statistically significant P values are underlined
Distribution of resistance genes in studied organisms
| Resistance Markers | Total (n = 73) |
| |||
|---|---|---|---|---|---|
|
| 34 (47%) | 6 (38%) | 27 (49%) | 1 | 0.5938 |
| PMQR (number) | 59 (81%) | 7 (44%) | 50 (91%) | 2 |
|
|
| 52 (71%) | 7 (44%) | 44 (80%) | 1 |
|
|
| 37 (51%) | 0 (0%) | 35 (64%) | 2 |
|
|
| 2 (3%) | 0 (0%) | 2 (4%) | 0 | 0.4391 |
|
| 55 (75%) | 2 (13%) | 53 (96%) | 0 |
|
|
| 48 (66%) | 8 (50%) | 38 (69%) | 2 | 0.2671 |
|
| 31 (42%) | 11 (69%) | 20 (36%) | 0 |
|
|
| 36 (49%) | 2 (13%) | 34 (62%) | 0 |
|
|
| 48 (66%) | 7 (44%) | 39 (71%) | 2 | 0.0883 |
|
| 18 (25%) | 0 (0%) | 18 (33%) | 0 |
|
Statistically significant P values are underlined
The difference between NDM-positive and NDM-negative isolates with respect to ciprofloxacin non-susceptibility and prevalence of PMQRs
| Characteristics | NDM-positive isolates [ | NDM-negative isolates [ | |
|---|---|---|---|
| Ciprofloxacin nonsusceptibility | 33 (97%) | 33 (85%) | 0.1607 |
| Isolates carrying PMQR | 29 (85%) | 30 (77%) | 0.5430 |
|
| 28 (82%) | 24 (62%) | 0.0890 |
|
| 19 (56%) | 18 (46%) | 0.5521 |
|
| 2 (6%) | 0 (0%) | 0.4139 |
|
| 27 (79%) | 28 (72%) | 0.6305 |
Fig. 1Genetic relatedness of (a) E. coli and (b) K. pneumoniae isolates. Analysis of PFGE of XbaI digestion pattern based on Dice’s similarity co-efficient and UPGMA (the position tolerance and optimization were set at 1.5 and 1.5% respectively). More than 95% similarity in PFGE band pattern was interpreted as indistinguishable
Fig. 2Genetic relatedness, the presence of PMQRs and chromosomal mutations and MIC values of meropenem and ciprofloxacin in NDM-positive (a) E. coli and (b) K. pneumoniae isolates. Analysis of PFGE of XbaI digestion pattern based on Dice’s similarity co-efficient and UPGMA (the position tolerance and optimization were set at 1.5 and 1.5% respectively). More than 95% similarity in PFGE band pattern interpreted as indistinguishable. MEM: meropenem, CIP: ciprofloxacin
Genotypic characterization of NDM-positive isolates co-transferring blaNDM-1 and PMQRs
| Strain no. | Organism | NDM | PMQR | Other Resistance genes | MEM MIC | CIP MIC | Plasmid size | Plasmid type | Plasmid addiction system | Integron |
|---|---|---|---|---|---|---|---|---|---|---|
| EN5132 |
|
|
|
| 2 | > 32 | 212, 6, 3 | FIB,A/C,FIIK,FII,N | PemK, CcdAB, Hok-Sok | intI1 |
| EN5132.T1 |
|
|
| 2 | 0.047 | 212 | A/C | – | intI1 | |
| EN5127 |
|
|
|
| 24 | > 32 | 210, 4,3 | A/C,FIIK,N | – | intI1 |
| EN5127.T1 |
|
|
| 2 | 0.016 | 210 | N, A/C | – | IntI1 | |
| EN5127.T2 |
|
|
| 6 | 0.5 | 210 | N, A/C | – | IntI1 | |
| EN5150 |
|
|
|
| 4 | > 32 | 248 | FIIK, | PemK | IntI1 |
| EN5150.T1 |
|
|
| 4 | 0.25 | 248 | FIIK, | – | IntI1 | |
| EN5150.T2 |
|
|
| 4 | 0.25 | 248 | FIIK, | IntI1 | ||
| EN5151 |
|
|
|
| 2 | > 32 | 248, 128 | FIIK, | – | IntI1 |
| EN5151.T1 |
|
|
| 1 | 0.064 | 248 | FIIK, | – | IntI1 | |
| EN5151.T2 |
|
|
| 0.5 | 0.047 | 248 | FIIK, | IntI1 | ||
| EN5163 |
|
|
|
| 6 | > 32 | 266, 154 | FIIK | – | IntI1 |
| EN5163.T1 |
|
|
| 3 | 0.125 | 266 | FIIK | – | IntI1 | |
| EN5163.T2 |
|
|
| 2 | 0.125 | 266 | FIIK | IntI1 | ||
| EN5165 |
|
|
|
| 12 | > 32 | 266, 154 | FIIK | – | IntI1 |
| EN5165.T1 |
|
|
| 0.38 | 0.75 | 266 | FIIK | IntI1 | ||
| EN5165.T2 |
|
|
| 2 | 0.064 | 266 | FIIK | IntI1 | ||
| EN5166 |
|
|
|
| 4 | > 32 | 266, 154 | FIIK | – | IntI1 |
| EN5166.T1 |
|
|
| 0.5 | 0.047 | 266 | FIIK | – | IntI1 | |
| EN5166.T2 |
|
|
| 3 | 0.064 | 266 | FIIK | IntI1 | ||
| EN5170 |
|
|
|
| 4 | > 32 | 260, 200 | FIIK | – | IntI1 |
| EN5170.T1 |
|
|
| 0.5 | 0.064 | 260 | FIIK | – | IntI1 | |
| EN5170.T2 |
|
|
| 0.5 | 0.25 | 260 | FIIK | IntI1 | ||
| EN5173 |
|
|
|
| 1.5 | > 32 | 116, 90 | FIIK, | – | IntI1 |
| EN5173.T1 |
|
|
| 0.5 | 0.094 | 116 | FIIK | – | IntI1 | |
| EN5173.T2 |
|
|
| 1 | 0.047 | 116 | FIIK | IntI1 | ||
| EN5174 |
|
|
|
| 3 | 16 | 260, 7, 5, 4 | FIIK, N, HIB-M | VagC/D | IntI1 |
| EN5174.T1 |
|
| 3 | 6 | 260, 7, 5, 4 | FIIK, N, HIB-M | Vagc/D | IntI1 | ||
| EN5181 |
|
|
|
| 2 | 14 | 220 | FIIK, FII | PemK | – |
| EN5181.T1 |
|
|
| 0.5 | 0.19 | 220 | FIIK | – | – | |
| EN5181.T2 |
|
|
| 0.75 | 0.19 | 220 | FIIK | – | – | |
| EN5185 |
|
|
|
| 3 | > 32 | 266, 154 | FIIK | – | IntI1 |
| EN5185.T1 |
|
|
| 0.5 | 0.032 | 266 | FIIK | – | IntI1 | |
| EN5185.T2 |
|
|
| 1.5 | 0.19 | 266 | FIIK | - | IntI1 |
MEM: meropenem, CIP: ciprofloxacin, (-): absent or untypable (in case of plasmid types), E. coli J53 Fox-azide or ‘.T1’ : transconjugants selected in cefoxitin (10μg/ml)-sodium azide (100μg/ml), ), E. coli J53 Cip-Azide or ‘.T2’ : transconjugants selected in ciprofloxacin (0.06 μg/ml)-sodium azide (100 μg/ml)
Genotypic characterization of NDM-positive isolates transferring only blaNDM gene
| Strain no. | Organism | NDM | PMQR | Other Resistance genes | MEM MIC | CIP MIC | Plasmid size in kb (approximately) | Plasmid type (Inc) | Plasmid addiction system | Integron |
|---|---|---|---|---|---|---|---|---|---|---|
| EN5134 |
|
|
|
| 24 | > 32 | 225, 158,4 | FIA, FII, I1A | PemK, CcdAB, Hok-Sok, PndCA | intI1 |
| EN5134.T1 |
|
|
| 2 | 0.012 | 121 | FII | – | intI1 | |
| EN5141 |
|
|
|
| 4 | > 32 | 246, 134, 6 | FIB, HIB-M, FII | PemK, Hok-Sok | – |
| EN5141.T1 |
|
|
| 1.5 | 0.008 | 246, 6 | HIB-M | – | – | |
| EN5143 |
|
|
|
| 4 | > 32 | 105,56, 9 | FIA, I1γ, FII, I1a | PndC/A | intI1 |
| EN5143.T1 |
|
|
| 1.5 | 0.008 | 105 | FIA, FII | – | intI1 | |
| EN5169 |
|
|
|
| > 32 | > 32 | 200, 5, 2 | I1A, FIA, FIB, FIIS, R, FII | PndCA, Hok-Sok, ccdAB, SrnBC, PemK | - |
| EN5169.T1 |
|
|
| 1 | 0.012 | 200,5 | I1A, | Pnd C/A | - | |
| EN5177 |
|
|
|
| 4 | > 32 | 163,126,55,5, 2 | FIB, FIIS | PemK | IntI1 |
| EN5177.T1 |
|
|
| 1 | 0.012 | 163,126 | FIB, FIIS | – | IntI1 | |
| EN5114 |
|
|
|
| 1.5 | 1.5 | 248 | HIB-M | PemK | intI1 |
| EN5114.T1 |
|
|
| 1.5 | 0.012 | 248,180 | HIB-M | – | - | |
| EN5117 |
|
|
|
| 1.5 | 1.5 | 248 | HIB-M | PemK | intI1 |
| EN5117.T1 |
|
|
| 1 | 0.016 | 248 | HIB-M | – | - | |
| EN5123 |
|
|
|
| 3 | 0.094 | 210, 20,7,5 | FIA, R, FIIK | – | intI1 |
| EN5123.T1 |
|
|
| 1 | 0.008 | 210,5 | FIIK | – | - | |
| EN5129 |
|
|
|
| 2 | 12 | 263,230,15.6,6.7, | FIIK, R | – | intI1 |
| EN5129.T1F-A | - |
|
| 0.023 | 0.19 | 230 | FIIK | – | - | |
| EN5130 |
|
|
|
| 8 | > 32 | 270,205,29,13, 8, 7, 6,5, 3, 2 | FIIK, FIA, X2 | – | intI1 |
| EN5130.T1F |
|
|
| 2 | < 0.002 | 270, 205, 29, 13, 8, 7,5, 3, 2 | – | – | - | |
| EN5135 |
|
|
|
| 1.5 | 16 | 230, 5, 4, 2, 0.1 | FIIK, HIB-M | VagCD, | intI1 |
| EN5135.T1 |
|
|
| 1.5 | 0.004 | 230 | HIB-M | – | – | |
| EN5136 |
|
|
|
| 3 | 4 | 340, 212, 9, 6, 4 | FIIK, HIB-M | PemK, CcdAB, VagCD, Hok-Sok | intI1 |
| EN5136.T1 |
|
|
| 0.75 | 0.012 | 340 | HIB-M | – | intI1 | |
| EN5137 |
|
|
|
| 1.5 | 32 | 310,162, 8, 6, 4 | FIIK, HIB-M | PemK, CcdAB, VagCD, Hok-Sok | intI1 |
| EN5137.T1 |
|
|
| 0.75 | 0.012 | 310 | HIB-M | – | - | |
| EN5139 |
|
|
|
| 1 | 16 | 250,112,5, 4 | FIIK, HIB-M | PemK, VagCD | intI1 |
| EN5139.T1 |
|
|
| 1.5 | 0.23 | 250 | HIB-M | – | - | |
| EN5142 |
|
|
|
| 8 | 2 | 248,104 | FIIK, FIB-M | – | intI1 |
| EN5142.T1 |
|
| - | 1.5 | 0.008 | 248, 104 | – | – | intI1 | |
| EN5144 |
|
|
|
| 2 | 6 | 227, 52, 5, 4 | HIB-M | – | - |
| EN5144.T1 |
|
|
| 0.5 | 0.016 | 227 | HIB-M | – | - | |
| EN5146 |
|
|
|
| 10 | > 32 | 192,164, 7 | FIA, A/C, FIIK | – | - |
| EN5146.T1F |
|
|
| 6 | < 0.002 | 164 | A/C | – | - | |
| EN5154 |
|
|
|
| 8 | > 32 | 241, 201, 34, 29,8, 6, 4,3 | FIIS, R, FIIK | PemK, VagCD | IntI1 |
| EN5154.T1F |
|
|
| 6 | 0.012 | 240, 4 | FIIS | – | IntI1 | |
| EN5175 |
|
|
|
| 3 | 4 | 123, 88,7,5,3 | N, FIIK, HIB-M | PemK, VagCD | IntI1 |
| EN5175.T1 |
|
|
| 1.5 | 0.012 | 123 | HIB-M | - | - | |
| EN5175.T2 | – |
|
| 0.023 | 0.125 | 96, 50 | N, FIIK | VagCD | - | |
| EN5180 |
|
|
|
| 32 | > 32 | 293,208,5,4 | A/C, FIIK, FIB-M, HIB-M | VagCD | IntI1 |
| EN5180.T1 |
|
|
| 1.5 | 0.016 | 208 | A/C | IntI1 | ||
| EN5186 |
|
|
|
| 6 | > 32 | 235,188,47,5, 3, | FII | – | IntI1,IntI2 |
| EN5186.T1 |
|
|
| 1.5 | 0.008 | 188 | - | - | IntI1 | |
| EN5131 |
|
|
|
| 4 | 4 | 205,27,17,7,5 | – | ccdA/B, hok -sok | intI1 |
| EN5131.T1 |
|
|
| 2 | < 0.002 | 205,27,7 | – | – |
MEM: meropenem, CIP: ciprofloxacin, (-) : absent or untypable (in case of plasmid types), E. coli J53 Fox-azide or ‘.T1’ : transconjugants selected in cefoxitin (10μg/ml)-sodium azide (100μg/ml), E. coli DH10B or ‘.TF’: Transformants selected in cefoxitin (5μg/ml) , ‘.TF-A : Transformants selected in ampicillin (50μg/ml), E. coli J53 Cip-Azide or ‘.T2’ : transconjugants selected in ciprofloxacin (0.06 μg/ml)-sodium azide (100 μg/ml)
Fig. 3Upstream and downstream regions of the blaNDM gene. Structure a was present in 5 isolates, structure b was present in 17 isolates, structure c and d were present in one isolate each and structure e was present in 3 isolates